BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 27091029)

  • 1. L-asparaginase-based regimens followed by allogeneic hematopoietic stem cell transplantation improve outcomes in aggressive natural killer cell leukemia.
    Jung KS; Cho SH; Kim SJ; Ko YH; Kang ES; Kim WS
    J Hematol Oncol; 2016 Apr; 9():41. PubMed ID: 27091029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction treatment with SMILE and consolidation with autologous stem cell transplantation for newly diagnosed stage IV extranodal natural killer/T-cell lymphoma patients.
    Kim SJ; Park S; Kang ES; Choi JY; Lim DH; Ko YH; Kim WS
    Ann Hematol; 2015 Jan; 94(1):71-8. PubMed ID: 25082384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia.
    Yamaguchi M; Suzuki R; Kwong YL; Kim WS; Hasegawa Y; Izutsu K; Suzumiya J; Okamura T; Nakamura S; Kawa K; Oshimi K
    Cancer Sci; 2008 May; 99(5):1016-20. PubMed ID: 18294294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008).
    Yoon DH; Kim SJ; Jeong SH; Shin DY; Bae SH; Hong J; Park SK; Yhim HY; Yang DH; Lee H; Kang HJ; Lee MH; Eom HS; Kwak JY; Lee JH; Suh C; Kim WS
    Oncotarget; 2016 Dec; 7(51):85584-85591. PubMed ID: 27542213
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment of extranodal natural killer/T-cell lymphoma, nasal type, complicated by severe hemophagocytic syndrome, with dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide chemotherapy followed by autologous stem cell transplant.
    Inoue D; Nagai Y; Takiuchi Y; Nagano S; Arima H; Kimura T; Shimoji S; Mori M; Togami K; Tabata S; Yanagita S; Matsushita A; Nagai K; Maruoka H; Imai Y; Suzuki R; Takahashi T
    Leuk Lymphoma; 2010 Apr; 51(4):720-3. PubMed ID: 20233057
    [No Abstract]   [Full Text] [Related]  

  • 6. Concurrent Chemoradiation Therapy Followed by Consolidation Chemotherapy for Localized Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
    Oh D; Ahn YC; Kim SJ; Kim WS; Ko YH
    Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):677-83. PubMed ID: 26461010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pretreatment EBV-DNA copy number is predictive of response and toxicities to SMILE chemotherapy for extranodal NK/T-cell lymphoma, nasal type.
    Ito Y; Kimura H; Maeda Y; Hashimoto C; Ishida F; Izutsu K; Fukushima N; Isobe Y; Takizawa J; Hasegawa Y; Kobayashi H; Okamura S; Kobayashi H; Yamaguchi M; Suzumiya J; Hyo R; Nakamura S; Kawa K; Oshimi K; Suzuki R
    Clin Cancer Res; 2012 Aug; 18(15):4183-90. PubMed ID: 22675173
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of advanced extranodal NK/T cell lymphoma, nasal-type and aggressive NK-cell leukemia.
    Suzuki R
    Int J Hematol; 2010 Dec; 92(5):697-701. PubMed ID: 21116747
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ifosfamide, methotrexate, etoposide, and prednisolone (IMEP) plus L-asparaginase as a first-line therapy improves outcomes in stage III/IV NK/T cell-lymphoma, nasal type (NTCL).
    Kim M; Kim TM; Kim KH; Keam B; Lee SH; Kim DW; Lee JS; Jeon YK; Kim CW; Heo DS
    Ann Hematol; 2015 Mar; 94(3):437-44. PubMed ID: 25300500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type.
    Xu PP; Xiong J; Cheng S; Zhao X; Wang CF; Cai G; Zhong HJ; Huang HY; Chen JY; Zhao WL
    EBioMedicine; 2017 Nov; 25():41-49. PubMed ID: 29056540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Aggressive natural killer cell leukemia: therapeutic potential of L-asparaginase and allogeneic hematopoietic stem cell transplantation.
    Ishida F; Ko YH; Kim WS; Suzumiya J; Isobe Y; Oshimi K; Nakamura S; Suzuki R
    Cancer Sci; 2012 Jun; 103(6):1079-83. PubMed ID: 22360679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extra-nodal natural killer/T cell lymphoma in elderly patients: the impact of aging on clinical outcomes and treatment tolerability.
    Kim SM; Park S; Oh DR; Ahn YC; Ko YH; Kim SJ; Kim WS
    Ann Hematol; 2016 Mar; 95(4):581-91. PubMed ID: 26729202
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pralatrexate as a bridge to allogeneic hematopoietic stem cell transplantation in a patient with advanced-stage extranodal nasal-type natural killer/T cell lymphoma refractory to first-line chemotherapy: a case report.
    Liu YC; Lin TA; Wang HY; Ko PS; Liu CJ; Hsiao LT; Chien SH; Gau JP
    J Med Case Rep; 2020 Mar; 14(1):43. PubMed ID: 32183896
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trial of LVDP regimen (L-asparaginase, etoposide, dexamethasone, and cisplatin, followed by radiotherapy) as first-line treatment for newly diagnosed, stage III/IV extranodal natural killer/T cell lymphoma.
    Wang YQ; Yang Y; Zhuo HY; Zou LQ; Jiang Y; Jiang M
    Med Oncol; 2015 Feb; 32(2):435. PubMed ID: 25572807
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and management of natural killer-cell malignancies.
    Ishida F; Kwong YL
    Expert Rev Hematol; 2010 Oct; 3(5):593-602. PubMed ID: 21083476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SMILE for natural killer/T-cell lymphoma: analysis of safety and efficacy from the Asia Lymphoma Study Group.
    Kwong YL; Kim WS; Lim ST; Kim SJ; Tang T; Tse E; Leung AY; Chim CS
    Blood; 2012 Oct; 120(15):2973-80. PubMed ID: 22919026
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epstein-Barr virus-associated natural killer/T-cell lymphomas.
    Asano N; Kato S; Nakamura S
    Best Pract Res Clin Haematol; 2013 Mar; 26(1):15-21. PubMed ID: 23768637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatments and Outcomes of Patients With Extranodal Natural Killer/T-Cell Lymphoma Diagnosed Between 2000 and 2013: A Cooperative Study in Japan.
    Yamaguchi M; Suzuki R; Oguchi M; Asano N; Amaki J; Akiba T; Maeda T; Itasaka S; Kubota N; Saito Y; Kobayashi Y; Itami J; Ueda K; Miyazaki K; Ii N; Tomita N; Sekiguchi N; Takizawa J; Saito B; Murayama T; Ando T; Wada H; Hyo R; Ejima Y; Hasegawa M; Katayama N
    J Clin Oncol; 2017 Jan; 35(1):32-39. PubMed ID: 28034070
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Successful treatment with high-dose methotrexate/cytarabine regimen in a patient in SMILE regimen-resistant extranodal natural killer/T-cell lymphoma].
    Saburi M; Itani K; Nagamatsu K; Miyazaki Y; Otsuka E; Urabe S; Saburi Y
    Rinsho Ketsueki; 2014 Jan; 55(1):120-4. PubMed ID: 24492044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DDGP versus SMILE in Newly Diagnosed Advanced Natural Killer/T-Cell Lymphoma: A Randomized Controlled, Multicenter, Open-label Study in China.
    Li X; Cui Y; Sun Z; Zhang L; Li L; Wang X; Wu J; Fu X; Ma W; Zhang X; Chang Y; Nan F; Li W; Su L; Wang J; Xue H; Zhang M
    Clin Cancer Res; 2016 Nov; 22(21):5223-5228. PubMed ID: 27060152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.